2017年8月8日 / 晚上8点37分 / 11 天前

BRIEF-Endocyte Q2 loss per share $0.28

Aug 8 (Reuters) - Endocyte Inc

* Endocyte reports second quarter financial results and provides clinical and pipeline update

* Q2 loss per share $0.28

* Endocyte - ‍plans to initiate clinical development for Car T-Cell program in osteosarcoma in 2018; IND filed for dual-targeted DNA crosslinker EC2629​

* Endocyte - sees cash, cash equivalents balance at end of 2017 about $105 million; full expense impact of restructuring expected to be realized by end of Q4 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below